StockNews.com initiated coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a report released on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, Oppenheimer restated an outperform rating and issued a $22.00 target price on shares of Corbus Pharmaceuticals in a report on Wednesday, August 9th. View […]